EUClinicalTrials.govClinical trialPhase 2Active, not recruiting
Neoadjuvant Capecitabine, Oxaliplatin, Docetaxel and Atezolizumab in Resectable Gastric and GE-junction Cancer (PANDA)
Official record
- Identifier
NCT03448835- Recruiting locations
country
Netherlands- Interventions studied
- AtezolizumabCapecitabineOxaliplatinDocetaxel
- Lead sponsor
- The Netherlands Cancer Institute
- Target enrolment
- 20 participants
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Status
- Active, not recruiting
- First posted
- Feb 28, 2018
- Last updated on the registry
- Sep 30, 2026
- Age
- 18 Years
- Sex
- ALL
- Study contact
- No public contact is listed on the official record.
- Eligibility criteria
Reproduced verbatim from the official record. Eligibility is decided by the study team, never by this page.
Inclusion Criteria: * signed informed consent * patients age 18 and older * primary resectable, histologically confirmed gastric or GEJ adenocarcinoma Exclusion Criteria: * no signs of distant metastases * no active or history of autoimmune disease or immune deficiency * no significant cardiovascular disease * no major surgical procedure within 4 weeks prior to initiation of study treatment * no current treatment with anti-viral therapy or HBV * no pregnancy or breastfeeding * no history of malignancy within 3 years prior to screening
- Indexed under
- Gastric Cancer